Drug intelligence / Profile preview

ranizurel

Development stage
Phase 3
Lead developer
Reliance Life Sciences
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Intravitreal
01

Overview

Ranizurel is a biosimilar of ranibizumab, a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment that selectively binds to and inhibits the biological activity of human vascular endothelial growth factor A (VEGF-A). By blocking VEGF-A, it prevents abnormal blood vessel growth and leakage in the eye. This mechanism helps treat vision loss associated with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema, diabetic retinopathy, myopic choroidal neovascularization (mCNV), and macular edema following retinal vein occlusion. Ranizurel is administered as an intravitreal injection by an ophthalmologist[2][5][8].

Brand names
RanizuRel
Other names
ranibizumab biosimilarRanizuRel
02

Targets

Beyond the preview

Go deeper on ranizurel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ranizurel.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call